Dye-sensitized solar cells (DSSCs) have attracted extensive interest in past decade as a promising candidate for the future generation of cost-effective photovoltaic solar cells. [1][2][3][4][5] Since the first demonstration of 10.4% photoconversion efficiency on TiO 2 -based DSSC, [6] intensive work in DSSC research has been devoted to the synthetic chemistry and structural and photovoltaic characterization of mesoporous nanocrystalline TiO 2 materials. [7][8][9] In contrast, other metal oxide semiconductors, such as tin and zinc oxides, have received less attention, though they have required band-gap widths and photoelectrochemical properties as TiO 2 . In fact, SnO 2 has at least two advantageous features compared to TiO 2 for DSSC applications: its higher electron mobility ($100-200 cm 2 V À1 S À1[10]) than TiO 2 ($0.1-1.0 cm 2 V À1 S À1[11]), suggesting a faster diffusion transport of photoinduced electrons in SnO 2 than in TiO 2 ; and its larger band gap (3.6 eV) than anatase TiO 2 (3.2 eV), which would create fewer oxidative holes in the valence band, so as to facilitate the long-term stability of DSSCs. However, SnO 2 -based DSSCs were developed with less success, and the conversion efficiencies of SnO 2 photoelectrodes reported so far are much less than those of TiO 2 . [12,13]

A self-decoupled porphyrin with a tripodal anchor has been synthesized and deposited on Au(111) using different wet-chemistry methods. Nanoscale electroluminescence from single porphyrin molecules or aggregates on Au(111) has been realized by tunneling electron excitation. The molecular origin of the luminescence is established by the vibrationally resolved fluorescence spectra observed. The rigid tripodal anchor not only acts as a decoupling spacer but also controls the orientation of the molecule. Intense molecular electroluminescence can be obtained from the emission enhancement provided by a good coupling between the molecular transition dipole and the axial nanocavity plasmon. The unipolar performance of the electroluminescence from the designed tripodal molecule suggests that the porphyrin molecule is likely to be excited by the injection of hot electrons, and then the excited state decays radiatively through Franck-Condon π*-π transitions. These results open up a new route to generating electrically driven nanoscale light sources.

The emulation of the complex cellular and bacterial vesicles used to transport materials through fluids has the potential to add revolutionary capabilities to fluidic platforms. Although a number of artificial motile vesicles or microdroplets have been demonstrated previously, control over their movement in liquid in 3D has not been achieved. Here it is shown that by adding a chemical "fuel," a photoactive material, to the droplet, it can be moved in any direction (3D) in water using simple light sources without the need for additives in the water. The droplets can be made up of a range of solvents and move with speeds as high as 10.4 mm s toward or away from the irradiation source as a result of a light-induced isothermal change in interfacial tension (Marangoni flow). It is further demonstrated that more complex functions can be accomplished by merging a photoactive droplet with a droplet carrying a "cargo" and moving the new larger droplet to a "reactor" droplet where the cargo undergoes a chemical reaction. The control and versatility of this light-activated, motile droplet system will open up new possibilities for fluidic chemical transport and applications.

Here we report that GNE-783, a novel checkpoint kinase-1 (CHK1) inhibitor, enhances the activity of gemcitabine by disabling the S-and G 2 cell-cycle checkpoints following DNA damage. Using a focused library of 51 DNA-damaging agents, we undertook a systematic screen using three different cell lines to determine which chemotherapeutics have their activity enhanced when combined with GNE-783. We found that GNE-783 was most effective at enhancing activity of antimetabolite-based DNA-damaging agents; however, there was a surprisingly wide range of activity within each class of agents. We, next, selected six different therapeutic agents and screened these in combination with GNE-783 across a panel of cell lines. This revealed a preference for enhanced chemopotentiation of select agents within tumor types, as, for instance, GNE-783 preferentially enhanced the activity of temozolomide only in melanoma cell lines. Additionally, although p53 mutant status was important for the overall response to combinations with some agents; our data indicate that this alone was insufficient to predict synergy. We finally compared the ability of a structurally related CHK1 inhibitor, GNE-900, to enhance the in vivo activity of gemcitabine, CPT-11, and temozolomide in xenograft models. GNE-900 significantly enhanced activity of only gemcitabine in vivo, suggesting that strong chemopotentiation in vitro can translate into chemopotentiation in vivo. In conclusion, our results show that selection of an appropriate agent to combine with a CHK1 inhibitor needs to be carefully evaluated in the context of the genetic background and tumor type in which it will be used. Mol Cancer Ther; 12(11); 2285-95. Ó2013 AACR.

No abstract

Fullerene derivatives with different addition patterns exhibit different physical, chemical, and biological properties, which are important for fullerene applications. Novel and rare 1,2,3,16-functionalized [60]fullerene derivatives having a five-membered heterocycle fused to a [5,6]-junction were obtained with high regioselectivity by electrochemical derivatization of a [60]fulleroindoline. The product structures were determined by spectroscopic data and single-crystal X-ray analysis. The obtained high regioselectivity was rationalized using theoretical calculations.

Checkpoint kinase 1 (ChK1) is a serine/threonine kinase that functions as a central mediator of the intra-S and G 2 -M cell-cycle checkpoints. Following DNA damage or replication stress, ChK1-mediated phosphorylation of downstream effectors delays cell-cycle progression so that the damaged genome can be repaired. As a therapeutic strategy, inhibition of ChK1 should potentiate the antitumor effect of chemotherapeutic agents by inactivating the postreplication checkpoint, causing premature entry into mitosis with damaged DNA resulting in mitotic catastrophe. Here, we describe the characterization of GNE-900, an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor. In combination with chemotherapeutic agents, GNE-900 sustains ATR/ATM signaling, enhances DNA damage, and induces apoptotic cell death. The kinetics of checkpoint abrogation seems to be more rapid in p53-mutant cells, resulting in premature mitotic entry and/or accelerated cell death. Importantly, we show that GNE-900 has little single-agent activity in the absence of chemotherapy and does not grossly potentiate the cytotoxicity of gemcitabine in normal bone marrow cells. In vivo scheduling studies show that optimal administration of the ChK1 inhibitor requires a defined lag between gemcitabine and GNE-900 administration. On the refined combination treatment schedule, gemcitabine's antitumor activity against chemotolerant xenografts is significantly enhanced and dose-dependent exacerbation of DNA damage correlates with extent of tumor growth inhibition. In summary, we show that in vivo potentiation of gemcitabine activity is mechanism based, with optimal efficacy observed when S-phase arrest and release is followed by checkpoint abrogation with a ChK1 inhibitor. Mol Cancer Ther; 12(10); 1968-80. Ó2013 AACR.

Activation of Checkpoint kinase 1 (Chk1) following DNA damage mediates cell cycle arrest to prevent cells with damaged DNA from entering mitosis. Here we provide a high-resolution analysis of cells as they undergo S- and G₂-checkpoint bypass in response to Chk1 inhibition with the selective Chk1 inhibitor GNE-783. Within 4–8 h of Chk1 inhibition following gemcitabine induced DNA damage, cells with both sub-4N and 4N DNA content prematurely enter mitosis. Coincident with premature transition into mitosis, levels of DNA damage dramatically increase and chromosomes condense and attempt to align along the metaphase plate. Despite an attempt to congress at the metaphase plate, chromosomes rapidly fragment and lose connection to the spindle microtubules. Gemcitabine mediated DNA damage promotes the formation of Rad51 foci; however, while Chk1 inhibition does not disrupt Rad51 foci that are formed in response to gemcitabine, these foci are lost as cells progress into mitosis. Premature entry into mitosis requires the Aurora, Cdk1/2 and Plk1 kinases and even though caspase-2 and -3 are activated upon mitotic exit, they are not required for cell death. Interestingly, p53, but not p21, deficiency enables checkpoint bypass and chemo-potentiation. Finally, we uncover a differential role for the Wee-1 checkpoint kinase in response to DNA damage, as Wee-1, but not Chk1, plays a more prominent role in the maintenance of S- and G₂-checkpoints in p53 proficient cells.